A Phase II Pivotal Trial to Evaluate the Safety and Efficacy of Nitrogen Mustard (NM) 0.02% Ointment Formulations in Patients With Stage I or IIA Mycosis Fungoides (MF)
This study will evaluate the efficacy, tolerability and safety of the topical application of mechlorethamine (MCH) formulations in patients with stage I or IIA mycosis fungoides (MF).
Stanford is not currently accepting new patients for this trial. You may want to check clinicaltrials.gov to see if other locations are recruiting.
- drug : mechlorethamine-MCH (nitrogen mustard)
Phase: Phase 2
Ages Eligible For Study:
- Patients with mycosis fungoides confirmed by a skin biopsy - Stage I or IIA patients must have been treated previously with prior topical therapies including PUVA, UVB, topical steroids, but not NM within the past 2 years, or topical carmustine (BCNU) - Patients must be otherwise healthy with acceptable organ function. - Prior to initiating study therapy, patients must not have had topical therapy within four weeks - Lab values within normal range - Willing/able to give consent - Must use effective means of contraception if of childbearing potential